Guideline Confusion for the Clinician

Stone NJ Robinson JG Lichtenstein AH . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63 (25 pt B):2889–2934.

Grundy SM Cleeman JI Merz CN . Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. Circulation. 2004;110 (2):227–239.

Hayward RA Krumholz HM . Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012;5 (1):2–5.

Whayne TF Jr . Assessment of low-density lipoprotein targets. Angiology. 2013;64 (6):411–416.

Whayne TF Jr . Low-density lipoprotein cholesterol targeting: a continued controversy. Angiology. 2014;65 (3):263–264.

Cannon CP Braunwald E McCabe CH . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350 (15):1495–1504.

Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285 (19):2486–2497.

Wilson PW D’Agostino RB Levy D Belanger AM Silbershatz H Kannel WB . Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97 (18):1837–1847.

Bottorff MB . Underidentification and undertreatment issues. J Manag Care Pharm. 2003;9 (1 suppl):6–8.

Pearson TA Laurora I Chu H Kafonek S . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160 (4):459–467.

Cabana MD Rand CS Powe NR . Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282 (15):1458–1465.

Doroodchi H Abdolrasulnia M Foster JA . Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract. 2008;9:42.

Athyros VG Katsiki N Karagiannis A Mikhailidis DP . The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps! Curr Med Res Opin. 2014;30 (9):1701–1705.

Mikhailidis DP Athyros VG . Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol. 2014;11 (2):72–74.

Stegman B Puri R Cho L . High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014;37(11): 3114–3120.

Athyros VG Papageorgiou AA Mercouris BR . Treatment with atorvastatin to the National Cholesterol Educational Program goal versus `usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18 (4):220–228.

Wiviott SD Cannon CP Morrow DA . Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46 (8):1411–1416.

Boekholdt SM Hovingh GK Mora S . Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64 (5):485–494.

Young SG Bertics SJ Curtiss LK Dubois BW Witztum JL . Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100. J Clin Invest. 1987;79 (6):1842–1851.

Kahn JA Glueck CJ . Familial hypobetalipoproteinemia. Absence of atherosclerosis in a postmortem study. JAMA. 1978;240 (1):47–48.

Liberopoulos EN Athyros VG Elisaf MS Mikhailidis DP . Targets for low-density lipoprotein cholesterol levels in patients with stable coronary heart disease: where are we now after the “treating to new targets” (TNT) trial? Hellenic J Cardiol. 2005;46 (3):161–164.

Leeper NJ Ardehali R deGoma EM Heidenreich PA . Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007;116 (6):613–618.

Levine AP Mikhailidis DP Moross T Benson K Gor M . Achieving vascular risk factor targets: a survey of a London general practice. Angiology. 2008;59 (1):36–46.

2013 Prevention Guidelines Tools: CV Risk Calculator; 2013. Web site. http://my.americanheart.org/professional/StatementsGuidelines/PreventionGuidelines/Prevention-Guidelines_UCM_457698_SubHomePage.jsp. Accessed October 14, 2014.

Hsia J MacFadyen JG Monyak J Ridker PM . Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57 (16):1666–1675.

Schwartz GG Olsson AG Ezekowitz MD . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285 (13):1711–1718.

Bruckert E Hayem G Dejager S Yau C Begaud B . Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19 (6):403–414.

Thompson PD Clarkson P Karas RH . Statin-associated myopathy. JAMA. 2003;289 (13):1681–1690.

Ward S Lloyd Jones M Pandor A . A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1–160, iii–iv.

Lenzer J . Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers. BMJ. 2013;347:f6989.

ACCF Relationship With Industry and Other Entities: Policies and Procedures for the Development of Guidelines and Other Clinical Documents; 2010. Web site. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx. Accessed November 3, 2014.

Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel m. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipidol. 2014;8 (1):29–60.

Miller N . Endocrinologists reject new cholesterol guidelines. Intern Med News. 2014;47(1).

NLA Recommendations for Patient-Centered Management of Dyslipidemia—Conclusions; 2014. Web site. https://www.lipid.org/recommendations/conclusions. Accessed November 3, 2014.

Jacobson TA Ito MK Maki KC . National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1—executive summary. J Clin Lipidol. 2014;8 (5):473–488.

Reiner Z Catapano AL De Backer G . ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32 (14):1769–1818.

European Atherosclerosis Society. New Guidelines in USA: How Do They Compare With the EAS/ESC Guidelines for the Management of Dyslipidaemia? Göteborg, Sweden: EAS; 2013.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339 (19):1349–1357.

Shepherd J Cobbe SM Ford I . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333 (20):1301–1307.

Sacks FM Pfeffer MA Moye LA . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335 (14):1001–1009.

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251 (3):351–364.

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251 (3):365–374.

Blankenhorn DH Johnson RL Nessim SA Azen SP Sanmarco ME Selzer RH . The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials. 1987;8 (4):356–387.

Blankenhorn DH Nessim SA Johnson RL Sanmarco ME Azen SP Cashin-Hemphill L . Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257 (23):3233–3240.

Buchwald H Stoller DK Campos CT Matts JP Varco RL . Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg. 1990;212(3):318–329; discussion 329-331.

Buchwald H Varco RL Boen JR . Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med. 1998;158 (11):1253–1261.

Koizumi J Koizumi I Uno Y . Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis. 1993;100 (1):65–74.

Kroon AA Aengevaeren WR van der Werf T . LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93 (10):1826–1835.

Baigent C Landray MJ Reith C . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377 (9784):2181–2192.

Schonfeld G . The hypobetalipoproteinemias. Annu Rev Nutr. 1995;15:23–34.